Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ENB003 · 1 trial · 5 indications
Based on observed or reported AEs. AEs will be evaluated and classified according to NCI CTCAE Version 5.0
Melanoma and Ovarian Cancer: • ORR, based on RECIST (evaluated in the context of ETBR expression)
| Arm | Type | Description |
|---|---|---|
| ENB003 150 ug + Pembrolizumab | EXPERIMENTAL | 150 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg) |
| ENB003 300 ug + Pembrolizumab | EXPERIMENTAL | 300 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg) |
| ENB003 500 ug + Pembrolizumab | EXPERIMENTAL | 500 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg) |
| ENB003 750 ug + Pembrolizumab | EXPERIMENTAL | 750 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg) |
| ENB003 1000 ug + Pembrolizumab | EXPERIMENTAL | 1000 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg) |
| ENB003 2000 ug + Pembrolizumab | EXPERIMENTAL | 2000 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg). In this treatment arm, ENB003 will be administered during each 21 day cycle, as opposed to every other cycle in early arms |
| ENB003 RP2D from dose escalation + Pembrolizumab | EXPERIMENTAL | The recommended phase 2 dose (RP2D) of ENB003 will be selected from the dose escalation portion of the study and administered in combination with a fixed dose of pembrolizumab (200mg) |
| Name | Type | Description |
|---|---|---|
| ENB003 | DRUG | ENB003 is selective Endothelin B Receptor Antagonist |
| Pembrolizumab | DRUG | anti-PD1 |
Subjects must fulfill all the following inclusion criteria relevant to their tumor type to be eligible for participation in the study: Inclusion Criteria Malignant Melanoma * Histopathologically confirmed diagnosis of advanced, unresectable or metastatic malignant melanoma. * Subjects may have re...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ENB003 is an investigational small molecule being developed for the treatment of cancer, including melanoma, ovary cancer, pancreatic cancer, and solid tumors. It is currently in Phase 1 clinical development and has not been approved by the FDA.
ENB003 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK on the New York Stock Exchange.
ENB003 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. It is being studied in a Phase 1b/2a trial in solid tumors.
ENB003 is being studied in clinical trial NCT04205227, titled 'ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors'. This trial is active but not recruiting, with an enrollment of 137 participants, and is being conducted in the United States and Australia.
Yes, ENB003 is being studied in combination with pembrolizumab in a Phase 1b/2a clinical trial for solid tumors. The trial is controlled and biomarker-selected, but it is not randomized or double-blind.